Dr.
Barry Marshall Shares
Xcelerate's Mission
In Advancing Medical Technology On
ticker NEWS'
Globally-Streamed
Broadcast
MAULDIN, SC -- May 13, 2021 -- InvestorsHub NewsWire
-- Xcelerate,
Inc's
(OTC: "XCRT") Nobel
Prize winner Dr.
Barry Marshall, AC. FRACP, FAA,FRS,MBBS-UWA,
who sits on
the Advisory Board of Xcelerate, Inc. shared the Company's mission of
advancing medical technology in live appearance on
Australia's
ticker NEWS'
globally
streamed broadcast.
In an in-depth interview,
Dr. Marshall spoke about Xcelerate's mission of finding innovative
acquisitions within the patent/engineering world. Currently Dr. Marshall is
working remotely with Xcelerate from his home in
Australia. Dr. Marshall spoke about
the significant advantages he has realized working with an American
listed public company, particularly in the area of funding. He also
shed light on his emerging role with Xcelerate and the great
respect he has for his friends in top management
at
Xcelerate. Dr. Marshall
is also
working to identify investment opportunities
in Australia on behalf of Xcelerate.
After winning the Nobel
Prize in Physiology or
Medicine in 2005,
Dr.
Marshall has been at the forefront
of the
biomedical industry for decades, where he studied the role
of the
bacterium Helicobacter pylori (H. pylori) in children, as well as
has acted as the Director of The Marshall
Centre for Infectious Diseases Research and
Training, founded in his
honor.
"Dr. Marshall's
contributions to Xcelerate's operations have already been
extraordinary and we look forward to our Nobel Prize winner getting
much more worldwide media exposure that can maximize our messaging
to the investment and medical communities," said Xcelerate CEO and
Director Michael O'Shea.
"We fully understand that
creating name recognition and public awareness is a critical
component for our success in the marketplace and we are extremely
confident that Dr. Marshall's appearance on ticker
News will be the first of many
such opportunities for our renowned top-tier professionals to share
their stories and Xcelerate's breaking news with a massive
audience," added O'Shea.
Dr. Marshall
interview https://xcelerate.global/press-release/
For more
information on Xcelerate, Inc, visit
www.xcelerate.global. and
follow them
on Twitter
@XcelerateUS.
ABOUT DR. BARRY MARSHALL, AC. FRACP, FAA, FRS, MBBS-UWA
Professor Barry Marshall
is a Nobel Prize Laureate, Professor of Clinical Microbiology at
The University of Western Australia. Professor Marshall (1974 UWA
graduate) was awarded the 2005 Nobel Prize for Physiology or
Medicine for their discovery of the bacterium Helicobacter pylori
(H. pylori) and its role in gastritis and peptic ulcer disease.
This discovery has benefited millions of people, maybe saving a
million lives over the last 10-20 years. Professor Marshall
returned to Perth and UWA in 1996 after a tenure at the University
of Virginia. Today, Professor Marshall is Director of The Marshall
Centre for Infectious Diseases Research and Training,
which
was founded in his honor. In
addition to H. pylori research, Marshall Centre is at the forefront
of infectious disease identification and surveillance, diagnostics
and drug design, and transformative discovery.
ABOUT XCELERATE
Xcelerate
is a company seeking innovative acquisitions within the
patent/engineering world and focused on joining early-stage medical
technology companies in a setting that is a controlled clinical
care where these new developments can be trailed, tested, and
applied.
SAFE
HARBOR
This
press release may contain forward-looking information within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), including all statements that are not
statements of historical fact regarding the intent, belief or
current expectations of the Company, its directors or its officers
with respect to, among other things: (i) the Company's financing
plans; (ii) trends affecting the Company's financial condition or
results of operations; (iii) the Company's growth strategy and
operating strategy; and (iv) the declaration and payment of
dividends. The words "may," "would," "will," "expect," "estimate,"
"anticipate," "believe," "intend," and similar expressions and
variations thereof are intended to identify forward-looking
statements. Investors are cautioned any such forward-looking
statements are not guarantees of future performance and involve
risks and uncertainties, many of which are beyond the Company's
ability to control, and actual results may differ materially from
those projected in forward-looking statements resulting
from various
factors.
Media
Contact: Justin Baronoff,
justin@transmediagroup.com (561)
750-9800